According to DelveInsight's analysis, the moderate-to-severe plaque psoriasis pipeline includes more than 30 leading companies actively developing more than 30 treatments.
Overview of moderate to severe plaque psoriasis:
Moderate to severe plaque psoriasis is the most common type of psoriasis, affecting 80% to 90% of people with the condition. It is an autoimmune disease that promotes the production of skin cells, causing the formation of thick, scaly patches known as plaques. These plaques typically appear on the elbows, knees, scalp, and back, and can also affect the nails, causing them to become discoloured, pitted, and peeling. Infection, stress, and skin injuries can trigger or worsen the condition, and symptoms fluctuate between periods of remission and flare-ups.
The exact cause of psoriasis vulgaris is still unknown, but genetics plays a significant role, with around one-third of cases having a family history. Researchers have identified specific gene mutations (PSORS1-PSORS9) that are associated with the condition, and environmental factors such as infection or exposure to toxins may also contribute. Diagnosis is usually based on the appearance of the skin, but in some cases, a biopsy may be needed to distinguish it from other skin conditions.
Plaque psoriasis can have a significant impact on a person's self-confidence and quality of life. There is no cure, but treatments aim to reduce recurrences and manage symptoms. Common treatments include topical corticosteroids, phototherapy (ultraviolet light exposure), vitamin D3 analogues, and retinoids. The condition persists throughout life, but advances in immunology and autoimmune research have led to more effective treatments and improved quality of life for patients.
For a detailed report on the moderate to severe plaque psoriasis pipeline, please see below. https://www.delveinsight.com/report-store/moderate-to-severe-plaque-psoriasis-pipeline-insight?utm_source=reportutm_medium=promotionutm_campaign=hpr
Key Takeaways from the Moderate to Severe Plaque Psoriasis Pipeline Report:
- DelveInsight's report highlights a robust pipeline with over 30 active companies developing more than 30 therapies to treat moderate to severe plaque psoriasis.
- Key players in this sector include Bristol-Myers Squibb, Akeso Biopharma, Jiangsu Hengrui Medicine, Nimbus Therapeutics, Sun Pharmaceutical Industries Limited, Suzhou Zelgen Biopharmaceuticals, GC Cell Corporation, Bioeq GmbH, Dong-A ST Co., Ltd., Can-fite Biopharma, Bio-thera Solutions, AbbVie, Sinocelltech, Janssen Research and Development, Innovent Biologics, Aurigene Discovery, Affibody, GlaxoSmithKline, Abcentra and others.
- Promising treatments in various stages of development include BMS-986165, AK111, and others.
Recent advances in the moderate to severe plaque psoriasis pipeline:
- November 2025:Johnson Johnson announced that its oral medication, icotrokinra, met its primary endpoint in a late-stage study in moderate-to-severe plaque psoriasis. The once-daily tablet significantly improved skin clearance, with 64.7% of patients showing substantial skin improvement and 49.6% experiencing a reduction in plaque severity, compared with 8.3% and 4.4% in the placebo group.
- 2025:Arctis Biotherapeutics's focus on dermatology treatments has seen its stock price soar: the company has introduced three FDA-approved drugs in less than two years and is seeking approval for two more by 2025. Its flagship product, Zoryve, addresses plaque psoriasis and seborrheic dermatitis, and it also offers a foam formulation for eczema.
Download a free sample page report on Moderate to Severe Plaque Psoriasis Pipeline Insights.https://www.delveinsight.com/sample-request/moderate-to-severe-plaque-psoriasis-pipeline-insight?utm_source=reportutm_medium=promotionutm_campaign=hpr
Moderate to severe plaque psoriasis pipeline analysis:
The report provides detailed insights into:
- Key companies developing therapies in the moderate to severe plaque psoriasis market.
- A comprehensive analysis of therapeutics at various stages of development, from early stage to late stage candidates.
- Evaluation of new drugs, including stage of development, route of administration, target receptors, monotherapy or combination therapy, mechanism of action, and type of molecule.
- Details of collaborations (both company-to-company and company-to-academic), licensing agreements, and funding that may impact the development of future treatments in the moderate to severe plaque psoriasis market.
To download the sample page report on Moderate to Severe Plaque Psoriasis Pipeline Insights, please visit:https://www.delveinsight.com/report-store/moderate-to-severe-plaque-psoriasis-pipeline-insight?utm_source=reportutm_medium=promotionutm_campaign=hpr
New drugs for moderate to severe plaque psoriasis:
- BMS-986165:Bristol-Myers Squibb
- AK111:Akeso Biopharma
Companies with moderate to severe plaque psoriasis:
- More than 30 companies are actively developing treatments for moderate to severe plaque psoriasis, including Bristol-Myers Squibb, which has an advanced drug candidate currently in the pre-registration stage.
DelveInsight's report covers more than 30 products at various stages of clinical development.
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early Stage Products (Phase I)
- Preclinical and discovery stage candidates
- Discontinued and inactive candidates
Moderate to severe plaque psoriasis pipeline treatments evaluated:
The report evaluates the following aspects of pipeline drugs:
- Rating by Product Type
- Rating by Developmental stages
- Rating by Route of administration(intravenous, subcutaneous, oral, intramuscular)
- Rating by Molecular Type(monoclonal antibodies, small molecules, peptides)
For more information on the moderate to severe plaque psoriasis treatment market, read the full report.
table of contents
- Introduction to the report
- Executive Summary
- Current treatment patterns for moderate to severe plaque psoriasis
- Moderate to Severe Plaque Psoriasis – A DelveInsight Perspective
- Treatment evaluation
- Moderate to severe plaque psoriasis Late-stage products (Phase III)
- Moderate to severe plaque psoriasis Mid-stage product (Phase II)
- Early Stage Products (Phase I)
- Preclinical and discovery stage products
- Inactive Products
- Dormant products
- Discontinued Products for Moderate to Severe Plaque Psoriasis
- Moderate to Severe Plaque Psoriasis Product Profile
- Major Players in Moderate to Severe Plaque Psoriasis
- Key Products for Moderate to Severe Plaque Psoriasis
- Inactive and Discontinued Products
- Unmet Needs in Moderate to Severe Plaque Psoriasis
- Future Outlook for Moderate to Severe Plaque Psoriasis
- Analyst Review of Moderate to Severe Plaque Psoriasis
- Appendix
- Reporting Methods
About DelveInsight
DelveInsight is a market research and consulting company specializing in the healthcare and life sciences sector, providing accurate market intelligence to support clients' business strategies. Our team of experienced experts analyzes the latest trends in the pharmaceutical, medical technology and biotechnology sectors and provides optimal solutions to companies across the globe.
Contact Information:
Himanshu
hmason@delveinsight.com
info@delveinsight.com
+14699457679
